User:Mr. Ibrahem/Naxitamab

Naxitamab, sold under the brand name Danyelza, is a medication used to treat neuroblastoma. It is used in those who are at least a year old with disease in the bone that have not responded sufficiently to other treatment. It is given by gradual injection into a vein. It is used with a granulocyte-macrophage colony-stimulating factor (GM-CSF).

Common side effects include infusion-related reaction, pain, fast heart rate, vomiting, cough, nausea, diarrhea, high blood pressure, tiredness, erythema multiforme, peripheral neuropathy, hives, fever, headache, injection site reaction, swelling, anxiety, and irritability. Other side effects may include transverse myelitis and reversible posterior leukoencephalopathy syndrome (RPLS). Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to GD2.

Naxitamab was approved for medical use in the United States in 2020. As of 2022 it is not approved in Europe or the United Kingdom. In the United States 40 mg of medication costs about 23,000 USD as of 2022.